Bölüm notları
GLP-1 Studio Podcast – Studio Special
Host: Amanda Bonello
On November 6th, 2025, the White House announced pricing agreements with Eli Lilly and Novo Nordisk that could reshape GLP-1 access for millions of Americans.
For the first time ever, Medicare and Medicaid will cover GLP-1 medications for obesity—with just a $50 copay. Brand name medications like Ozempic, Wegovy, and Zepbound are coming down to Most-Favored-Nation pricing, finally putting Americans on par with what other countries pay.
Discounted cash pay prices through TrumpRx are expected by the end of 2025. The full Medicare and…
Web sitesi: newsletter.glp1studio.com

